Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: Is it still reasonable?

Expert Review of Hematology

Volumn 4, Issue 2, 2011, Pages 153-159

  Rudzki, Jakob ^a   Wolf, Dominik ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

chronic myeloid leukemia; chronic phase; CML; high dose; imatinib

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AP 24534; BUSULFAN; CYTARABINE; DASATINIB; DAUNORUBICIN; HYDROXYUREA; IMATINIB; NILOTINIB; PONATINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BONE MARROW SUPPRESSION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG TOLERABILITY; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LIVER TOXICITY; META ANALYSIS; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 79955050286     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.11.9     Document Type: Review

References (35)

1. Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J. Clin. Oncol. 27(35), 6041-6051 (2009).
2. Hughes TP, Hochhaus A, Branford S et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS).Blood 116(19), 3758-3765 (2010).
3. Druker B, Guilhot F, O'Brien S et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408-2417 (2006). (Pubitemid 44903745)
4. Cortes J, Talpaz M, O'Brien S et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. 11(9), 3425-3432 (2005). (Pubitemid 40627896)
5. Löwenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361(13), 1235-1248 (2009).
6. Fernandez HF, Sun Z, Yao X et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361(13), 1249-1259 (2009).
7. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031-1037 (2001). (Pubitemid 32267972)
8. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346(9), 645-652 (2002). (Pubitemid 34815868)
9. Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW. Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. J. Clin. Oncol. 28(11), e169-e171 (2010).
10. O'Hare T, Shakespeare WC, Zhu X et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5), 401-412 (2009).
11. Cortes J, Talpaz M, Bixby D et al. A Phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Presented at: 52nd ASH Annual Meeting and Exposition. Orlando, FL, USA, 4-7 December 2010.
12. Kantarjian H, Talpaz M, O'Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2), 473-475 (2003). (Pubitemid 36077567)
13. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin. Cancer Res. 9(6), 2092-2097 (2003). (Pubitemid 36687630)
14. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 102(7), 2702-2703 (2003).
15. Breccia M, Stagno F, Vigneri P et al. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. Am. J. Hematol. 85(5), 375-377 (2010).
16. Rea D, Etienne G, Corm S et al. Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primarysuboptimal response to imatinib 400 mg daily standard therapy. Leukemia 23(6), 1193-1196 (2009).
17. Jabbour E, Kantarjian H, Jones D et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113(10), 2154-2160 (2009).
18. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6), 1809-1820 (2006). (Pubitemid 44394987)
19. Kantarjian H, Larson R, Guilhot F et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3), 551-560 (2009).
20. Koh Y, Kim I, Yoon SS et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard-dose imatiniby. Ann. Hematol. 89(7), 725-731 (2010).
21. Kantarjian H, Pasquini R, Lévy V et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized Phase 2 study (START-R).Cancer 115(18), 4136-4147 (2009).
22. Cervantes F, López-Garrido P, Montero MI et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 95(8), 1317-1324 (2010).
23. Yeung DT, Osborn M, White DL et al. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL-II Trial. Presented at: 52nd ASH Annual Meeting and Exposition. Orlando, FL, USA, 4-7 December 2010.
24. Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8), 3496-3499 (2007). (Pubitemid 46572540)
25. Larson R, Druker B, Guilhot F et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8), 4022-4028 (2008).
26. White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110(12), 4064-4072 (2007). (Pubitemid 350248463)
27. Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp. Hematol. 33(7), 767-775 (2005). (Pubitemid 40826590)
28. Kantarjian H, Talpaz M, O'Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103(8), 2873-2878 (2004). (Pubitemid 38451654)
29. Castagnetti F, Palandri F, Amabile M et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood 113(15), 3428-3434 (2009).
30. Hughes TP, Branford S, White DL et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112(10), 3965-3973 (2008).
31. Cortes JE, Baccarani M, Guilhot F et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28(3), 424-430 (2010).
32. Baccarani M, Rosti G, Castagnetti F et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113(19), 4497-4504 (2009).
33. Petzer AL, Wolf D, Fong D et al. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 'ISTAHIT' study. Haematologica 95(6), 908-913 (2010).
34. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2251-2259 (2010).
35. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362(24), 2260-2270 (2010).